Compare OZK & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZK | IMVT |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.0B |
| IPO Year | N/A | 2019 |
| Metric | OZK | IMVT |
|---|---|---|
| Price | $45.35 | $25.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $54.11 | $30.78 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 04-15-2026 | 02-06-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.09 | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.73 | $12.72 |
| 52 Week High | $53.66 | $29.25 |
| Indicator | OZK | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 52.15 |
| Support Level | $44.25 | $24.63 |
| Resistance Level | $45.55 | $26.17 |
| Average True Range (ATR) | 1.10 | 1.16 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 95.20 | 76.19 |
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit, and individual retirement accounts to loan services like real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking, and other related services.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.